| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $1,402,500 | 1 | 6 |
Sells | $2,271,224 | 17 | 94 |
| Cohen Fred E | director | 1 | $1.4M | 0 | $0 | $1.4M |
| Schultes Birgit C | EVP, Chief Scientific Officer | 0 | $0 | 1 | $78,359 | $-78,359 |
| Dube Michael P | VP, Chief Accounting Officer | 0 | $0 | 3 | $95,014 | $-95,014 |
| Clark Eliana | EVP, Chief Technical Officer | 0 | $0 | 2 | $95,998 | $-95,998 |
| Lebwohl David | EVP, Chief Medical Officer | 0 | $0 | 1 | $109,627 | $-109,627 |
| BASTA JAMES | EVP, General Counsel | 0 | $0 | 2 | $112,444 | $-112,444 |
| Dulac Edward J III | EVP, Chief Financial Officer | 0 | $0 | 3 | $234,185 | $-234,185 |
| LEONARD JOHN M | President and CEO | 0 | $0 | 5 | $1.55M | $-1.55M |
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex …
Over the last 12 months, insiders at Intellia Therapeutics, Inc. have bought $1.4M and sold $2.27M worth of Intellia Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Intellia Therapeutics, Inc. have bought $1.2M and sold $1.43M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Cohen Fred E (director) — $1.4M.
The last purchase of 150,000 shares for transaction amount of $1.4M was made by Cohen Fred E (director) on 2026‑01‑05.
| 2026-11-02 | Sale | LEONARD JOHN M | President and CEO | 9,000 0.0069% | $11.99 | $107,910 | -1.08% | |
| 2026-10-02 | Sale | Dube Michael P | VP, Chief Accounting Officer | 1,864 0.0014% | $12.43 | $23,170 | -3.34% | |
| 2026-08-21 | Sale | LEONARD JOHN M | President and CEO | 2,785 0.0021% | $13.00 | $36,205 | -4.91% | |
| 2026-08-20 | Sale | LEONARD JOHN M | President and CEO | 19,890 0.0151% | $12.60 | $250,614 | -1.81% | |
| 2026-07-22 | Sale | Dulac Edward J III | EVP, Chief Financial Officer | 8,111 0.0073% | $11.25 | $91,249 | +8.00% | |
| 2026-07-02 | Sale | Dulac Edward J III | EVP, Chief Financial Officer | 4,677 0.0043% | $18.00 | $84,186 | -31.41% | |
| 2026-07-01 | Sale | Dube Michael P | VP, Chief Accounting Officer | 2,641 0.0023% | $16.78 | $44,316 | -30.05% | |
| 2026-03-02 | Sale | BASTA JAMES | EVP, General Counsel | 1,211 0.001% | $13.78 | $16,688 | -16.84% | |
| 2026-03-02 | Sale | Clark Eliana | EVP, Chief Technical Officer | 607 0.0005% | $13.78 | $8,364 | -16.84% | |
| 2026-01-05 | Sale | LEONARD JOHN M | President and CEO | 34,146 0.032% | $9.21 | $314,485 | +36.93% | |
| 2026-01-05 | Sale | Lebwohl David | EVP, Chief Medical Officer | 11,903 0.0112% | $9.21 | $109,627 | +36.93% | |
| 2026-01-05 | Sale | BASTA JAMES | EVP, General Counsel | 10,397 0.0098% | $9.21 | $95,756 | +36.93% | |
| 2026-01-05 | Sale | Dulac Edward J III | EVP, Chief Financial Officer | 6,379 0.006% | $9.21 | $58,751 | +36.93% | |
| 2026-01-05 | Sale | Schultes Birgit C | EVP, Chief Scientific Officer | 8,508 0.008% | $9.21 | $78,359 | +36.93% | |
| 2026-01-05 | Sale | Clark Eliana | EVP, Chief Technical Officer | 9,515 0.0089% | $9.21 | $87,633 | +36.93% | |
| 2026-01-05 | Sale | Dube Michael P | VP, Chief Accounting Officer | 2,989 0.0028% | $9.21 | $27,529 | +36.93% | |
| 2026-01-05 | Cohen Fred E | director | 150,000 0.1428% | $9.35 | $1.4M | +36.93% | ||
| 2025-12-11 | Sale | LEONARD JOHN M | President and CEO | 88,146 0.0835% | $9.49 | $836,384 | +33.35% | |
| 2025-10-01 | Sale | Schultes Birgit C | EVP, Chief Scientific Officer | 31 <0.0001% | $17.38 | $539 | -31.72% | |
| 2025-10-01 | Sale | Dube Michael P | VP, Chief Accounting Officer | 1,871 0.0018% | $17.38 | $32,518 | -31.72% |
| Cohen Fred E | director | 207453 0.148% | $2.46M | 1 | 0 | |
| Novartis Institutes for BioMedical Research, Inc. | 10 percent owner | 4129903 2.9473% | $48.98M | 1 | 1 | <0.0001% |
| ORBIMED ADVISORS LLC | director | 2662180 1.8998% | $31.57M | 1 | 0 | <0.0001% |
| GORDON CARL L | director | 2662180 1.8998% | $31.57M | 1 | 0 | <0.0001% |
| BAKER BROS. ADVISORS LP | 976214 0.6967% | $11.58M | 1 | 0 | <0.0001% | |
| Temasek Holdings (Private) Ltd | 10 percent owner | 790527 0.5642% | $9.38M | 1 | 0 | <0.0001% |
| CHASE WILLIAM J | director | 134693 0.0961% | $1.6M | 1 | 0 | +26.25% |
| SCHIERMEIER ANDREW | EVP, Chief Operating Officer | 16656 0.0119% | $197,540.16 | 1 | 1 | <0.0001% |
$8,217,280 | 112 | 46.33% | $1.6B | |
$607,395,062 | 99 | 4.23% | $1.88B | |
$54,660,406 | 66 | 22.24% | $1.5B | |
$61,893,001 | 38 | 19.63% | $1.89B | |
$530,111,731 | 35 | 8.69% | $1.51B |
| Increased Positions | 170 | +52.15% | 21M | +20.56% |
| Decreased Positions | 142 | -43.56% | 21M | -20.4% |
| New Positions | 72 | New | 4M | New |
| Sold Out Positions | 53 | Sold Out | 6M | Sold Out |
| Total Postitions | 354 | +8.59% | 104M | +0.15% |
| Ark Investment Management Llc | $109,776.00 | 10.28% | 11.92M | -1M | -8.44% | 2025-09-30 |
| Vanguard Group Inc | $101,723.00 | 9.52% | 11.04M | +192,651 | +1.77% | 2025-09-30 |
| Blackrock, Inc. | $85,430.00 | 8% | 9.28M | -751,358 | -7.49% | 2025-09-30 |
| Morgan Stanley | $55,468.00 | 5.19% | 6.02M | +2M | +46.29% | 2025-09-30 |
| Contrarius Group Holdings Ltd | $54,246.00 | 5.08% | 5.89M | +4M | +279.38% | 2025-09-30 |
| State Street Corp | $45,782.00 | 4.29% | 4.97M | +931,584 | +23.06% | 2025-09-30 |
| Goldman Sachs Group Inc | $39,407.00 | 3.69% | 4.28M | +2M | +109% | 2025-09-30 |
| Regeneron Pharmaceuticals, Inc. | $34,105.00 | 3.19% | 3.7M | 0 | 0% | 2025-09-30 |
| Baker Bros. Advisors Lp | $25,297.00 | 2.37% | 2.75M | +71,000 | +2.65% | 2025-09-30 |
| Geode Capital Management, Llc | $23,843.00 | 2.23% | 2.59M | -17,368 | -0.67% | 2025-09-30 |